All posts by imreal

Anderson Orthopaedic Clinic Opens State-of-the-Art Surgery Center, Completes First Robotic-Assisted Knee Replacement


News Image

Today, Anderson Orthopaedic Clinic, a leader in comprehensive orthopedic services and an M2 Orthopedics (M2O)-backed practice, is announcing the opening of a groundbreaking new facility for orthopedic surgeries, along with the first VELYS™ Robotic-Assisted knee replacement surgery in an Ambulatory Surgery Center (ASC) in the state of Maryland. The Harborside Surgery Center is well-known in the D.C. area as the premier facility for orthopedic surgeries, and with the launch of the new space, patients with complex cases can be managed more efficiently with large procedure rooms, state-of-the-art equipment, and improved amenities.

William G. Hamilton, MD, a fellowship-trained specialist in the field of hip and knee reconstruction and one of the leading joint replacement surgeons in the area, performed the VELYS™ Robotic-Assisted surgery, which uses intra-operative data unique to each patient. During the procedure, the technology is utilized to increase the accuracy and precision of the knee replacement, allowing patients to get back to their daily routine faster by optimizing surgical outcomes. The state-of-the-art technology simplifies total knee arthroplasty and offers versatile execution, verified performance, and valuable insights to maximize efficiency for surgeons and optimize patient outcomes.

“This is a hallmark moment for Anderson – in our eight decades of serving the D.C. area, we continue to look for new opportunities to expand our services and innovate. The opening of this surgery center and the integration of next-generation robotics in the outpatient setting allows us to serve our patients in even more meaningful ways,” said George C. Branche, III, MD, Medical Director of Harborside and surgeon with The Anderson Clinic. “As a premium destination for orthopedic surgeries, Harborside boasts some of the best surgeons from the DMV, including top physicians from our own clinic as well as Dr. Cassie G. Root, Dr. Ben W. Kittredge, IV, Dr. Michael Nathan, Dr. David Weintritt, and Dr. Andrew B. Wolff, who all share our commitment to quality care and outcomes.”

Nearly 60% of surgeries in the U.S. are performed in an ambulatory setting – at Harborside, patients have access to top surgeons and a modern, high-quality, and comfortable environment that is an optimal alternative to the traditional hospital setting. Harborside represents the forefront of innovative surgery centers with room for growth and future expansion. The focus on superior care and performance includes upgraded airflow, natural light, and increased privacy.

Additional features include:


  • -Improved patient amenities like valet parking, covered drop-off/pick-up, bright and spacious waiting rooms with workstations for guests, and private rooms for overnight stays
  • -Improved physician amenities, including private offices, larger locker rooms w/ showers, bike rack, larger staff lounge, etc.

Harborside Surgery Center meets the highest industry standards for top-quality health care, is certified by Medicare, is licensed by the state, and is fully accredited by the Accreditation Association for Ambulatory Health Care (AAAHC).

For more information, visit https://harborsidesurgcenter.com/.

About Anderson Orthopaedic Clinic

Anderson Orthopaedic Clinic is widely recognized as a national leader in comprehensive orthopaedic services. The board-certified physicians of The Anderson Clinic have received specialized training in orthopaedic surgery and in subspecialty areas within the field of orthopaedic medicine and can diagnose and treat the most complicated orthopaedic conditions.

For more information, visit https://andersonclinic.com

About M2 Orthopedics

M2 Orthopedics is modernizing practice management for the nation’s best orthopedic practices and surgeons so they can focus on patient care. By combining expertise in orthopedics with a unique focus on long-term physician partnerships, M2O supports private practices through enhanced management capabilities and access to capital – empowering practices to sustain their independence and growth. M2O enables physicians to prioritize exceptional care and experiences so everyone has better outcomes – patients win, practices succeed, and ultimately, the broader orthopedic field thrives.

For more information, visit http://www.m2orthopartners.com

Share article on social media or email:

Well Traveled Releases a Novel Travel Supplement Featuring IMMUSE™


Powerful immune support with clean, natural, and clinically-studied ingredients for unmatched efficacy. gowelltraveled.com

“When working on this new endeavor, the number one priority was to make sure the products were clean and used clinically- researched ingredients, so I turned to nutrition experts to achieve the right formula

Avid traveler and Well Traveled founder Patrick Firlik knows firsthand how debilitating travel can be for the immune and digestive systems. Seven years working as a management consultant combined with a personal passion for exploring the world, meant Patrick was on the road a lot. He started Well Traveled to address the pain points he experienced while traveling.

“When I was away from home, my routines were disrupted, I was exposed to lots of germs, and sometimes stressed. As a result, I often found myself sick, dehydrated, tired, lacking focus, and not eating or sleeping well. I was far from my best and I was tired of using sugary, artificial products that were moderately effective. That’s when I realized there had to be a better way to stay well on the road,” comments Firlik, adding, “When working on this new endeavor, the number one priority was to make sure the products were clean and used clinically- researched ingredients, so I turned to nutrition experts to achieve the right formula,” Firlik said.

Well Traveled Immune Activator is the first product of this exceptional wellness venture that aims to keep travelers well while on the road. It contains 50mg of IMMUSE™ LC-plasma, a postbiotic that proactively supports the immune system through a novel method of activation of pDC (plasmacytoid dendritic cells)*. The pDC, a rare type of immune cell, has been shown to activate pivotal cells, such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support*. IMMUSE™ is backed by 30 published studies, including 15 human clinical trials and over 10 years of research. IMMUSE™ is supplied by Kyowa Hakko, an international ingredients manufacturer whose primary goal is to provide health solutions that support optimal health for improved quality of life.

“As we are all traveling more, supporting immune system health is more important than ever, and we are pleased to see our IMMUSE™ ingredient formulated into such an innovative supplement,” commented Karen Todd, MBA, RD, Vice President Global Brand Marketing, Kyowa Hakko USA, Inc. “This is the first time that a brand is addressing the health needs of travelers in such a comprehensive way.”

What makes Well Traveled Immune Activator so unique is the combination of postbiotic and prebiotic, IMMUSE™ and BeniCaros, which creates gut-mediated immune activation, a mechanism uncommon in the space. The result is a powerful, triple action effect that strengthens the body’s natural defenses*, activates faster immune response*, and accelerates recovery*.

Traveling, especially by plane, causes adverse effects on the body, such as stress, dehydration, fatigue, bloating, and reduced blood flow. Well Traveled Immune Activator is a daily and convenient immune support supplement that helps the body combat these negative effects, a timely advantage now as the demand for business travel continues to build. According to the 2023 Traveler Values Index, about a third (32%) of consumers plan to take a business trip in the next 12 months, including more than 3 in 5 (62%) remote workers. This is a significant increase from April 2022, when only 16% of consumers said they would travel for business in the next 12 months. Not only are consumers planning to travel for work again, but 85% of business travelers also said they are excited to travel for work, opening up opportunities for brands like Well Traveled to serve travelers’ health and wellness needs.

*The Food and Drug Administration has not evaluated these statements. This product is not intended to diagnose, treat, cure or prevent any disease.

Well Traveled Immune Activator with IMMUSE™ can be purchased on the Well Traveled website at https://www.gowelltraveled.com/.

To learn more about IMMUSE™, please visit: https://immusehealth.com/

Media interested in setting up an interview with Karen Todd, please get in touch with Giselle Chollett: at giselle@adinnyc.com or 917.386.7116.

About IMMUSE:

IMMUSE™ is a postbiotic that delivers a new, breakthrough approach to broad range immune support*. As a clinically researched immune activator* supported by 30 published studies, including 15 human trials, IMMUSE™ proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells)*. The pDC, a rare type of immune cell, functions as a key leader of the immune system and has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support*. Its unique mechanism of action, discovered by Kyowa Hakko’s parent company Kirin Holdings Co., Ltd., is opening doors for discovering postbiotics concerning immune health.

About Kyowa Hakko USA:

Kyowa Hakko USA is the North & South American office of Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing pharmaceuticals, nutraceuticals, and food & beverage products. Kyowa is the maker of branded ingredients, including IMMUSE™ LC-Plasma, Eyemuse™ Lacticaseibacillus paracasei KW3110, Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as L-Alanyl-L-Glutamine. For more information, visit http://www.kyowa-usa.com.

About Well Traveled:

Well Traveled is reimagining travel wellness with clean, natural, and clinically-proven supplements for the modern traveler to stay well on the road. We address the many pain points of travelers, starting with immune support. Well Traveled is for those who enjoy the thrill of the road and exploring new places but prioritize their health and wellbeing. Learn more: https://gowelltraveled.com/

Churches’ Medical Missions Can Qualify for empty tomb®, inc. Mission Match® Matching Contributions


The church can apply for a matching contribution in amounts from $500 up to $3,000, in $500 increments.

Mission Match®, a project of empty tomb®, inc., has matching funds available. A church congregation can apply for matching contributions for their new or expanded medical mission projects.

The matching contributions are available for projects to be done in Jesus’ name in one of 40 countries. These 40 countries were behind the curve in reducing the rate of under-age-5 child deaths as of 2015.

The church’s project can help provide medical workers, a medical facility’s special need, or supplies to address child survival.

The church can apply for a matching contribution in amounts from $500 up to $3,000, in $500 increments.

A review of denominational Web sites found examples of medical mission needs in some of the 40 countries. Such needs included: a portable ultrasound machine; malaria nets to be combined with church planting; and rebuilding a maternity wing on a hospital in an area devastated by civil war.

The list of 40 countries is available on missionmatch.org on the 40 Countries page.

Churches can find the Application at missionmatch.org on the Church Application page.

Once the application is accepted, the church will have 90 days to have one or more special offerings to raise the money to be matched. It’s important that everyone in the congregation has an opportunity to contribute.

When at least the amount of money in the application is raised, Mission Match sends a check to the church for the matching contribution amount requested on the application. The church then sends the combined amount to the denominational office or nonprofit doing the actual outreach.

More information is at missionmatch.org.

Share article on social media or email:

SciShield Receives Equity Investment from Strattam Capital to Revolutionize Laboratory EHS


SciShield, a leading provider of safety and regulatory compliance management software for scientific laboratories, has announced a partnership with Strattam Capital to accelerate product innovation and continue to deliver exceptional outcomes for its customers. Founded in 2003, SciShield supports commercial and academic organizations that house many of the nation’s most prestigious labs. SciShield was built from the ground up with scientists in mind, leading to high end-user engagement that drives comprehensive visibility for safety and compliance professionals.

While striving to meet the complex needs of laboratory environments, many organizations have accumulated a patchwork of customized, homegrown, and generic EHS solutions tied together by manual processes. This has resulted in frustrated end-users, high operating costs, and poor visibility for EHS professionals. As a bench researcher and lab supervisor, Nathan Watson, SciShield’s Founder and Chief Executive Officer, experienced firsthand the administrative burden that diverted precious time and resources from scientific discovery. He founded SciShield to solve this problem.

SciShield is a comprehensive and highly automated platform, led by ChemTracker, the industry’s premier chemical inventory management and regulatory reporting solution. In addition to serving as the EHS system of record for laboratories, SciShield frees scientists from burdensome administrative tasks, letting them safely focus their time and energy on scientific research. Due to the unique needs of their in-house scientists, companies that use enterprise-wide EHSQ systems are increasingly utilizing SciShield in their lab environments.

“By partnering with our community, we have fundamentally changed how scientists and EHS professionals work together to meet safety and compliance requirements in laboratories,” said Nathan Watson. “The investment by Strattam will accelerate SciShield’s ability to deliver solutions that further support scientific discovery and drive cost-effective, sustainable operations.”

SciShield is expanding its product and engineering teams to meet customer-led demand for innovative new solutions. This includes building out the infrastructure to support a connected ecosystem of solutions through partnerships and new software tools brought in under the SciShield umbrella. The company is also investing in its customer success organization to ensure that its growing customer base continues to enjoy dramatic efficiency gains while achieving their safety, security, and compliance goals.

“We are very impressed with the unwavering vision and deep care that the SciShield team has for the scientific community they serve,” said Neil Willis, Partner, Strattam Capital. “SciShield is on a mission to redefine laboratory safety and compliance, and we’re excited to be partnering with Nathan and the entire SciShield team as they release new innovative products to help their customers navigate an increasingly complex regulatory environment with ease.”

About SciShield

SciShield reduces burden on scientists worldwide while increasing safety, regulatory compliance, and operational efficiency for their organizations through our modular, enterprise software solutions. SciShield’s customers range from small biotechs and life science incubators to over a third of the top-tier (R1) research institutions, and top-10 pharmaceutical companies. Free your scientists from the burden with SciShield.com.

About Strattam Capital

Strattam Capital invests in founder-led, independent, B2B software and technology companies across North America. We believe in aligning with founders and CEOs before signing, via our Five-Point Plan process to allow execution with purpose, excitement, and efficiency. Headquartered in Austin, TX, we connect companies with the people, process, and scale needed to reach their potential. For more information, visit Strattam.com.

Share article on social media or email:

God’s Children Were Not Made for Mediocrity and Should Not Be Living in It


News Image

Through these years, I have been faced with the sad reality that many do not understand the purpose of God for them or know how to walk in it. I am pained to see believers (Kings and Queens) still living below royalty, and not accustomed to their divinity.

Author Famous Pullen, MD, invites Christians to use their God-given qualities to live their best lives in Abiding and Fellowship: The Only Way to Growth and Fruitfulness in Christ and in the Kingdom ($15.99, paperback, 9781662874710; $7.99, e-book, 9781662874727).

Pullen uses a combination of Bible stories, personal reflection, spiritual exercises and study aids to help believers grow and be fruitful in Christ.

“Through these years, I have been faced with the sad reality that many do not understand the purpose of God for them or know how to walk in it. I am pained to see believers (Kings and Queens) still living below royalty, and not accustomed to their divinity. This book is an attempt to turn the tide and set believers ablaze in their true calling,” said Pullen.

Dr. Famous Pullen is a speaker, teacher and fitness consultant residing in Toronto, Canada. He is the founder and president of GEM (Get Equipped Mission), a mission aimed at “revealing the kingdom, equipping people, and transforming the world” with a vision to see a world dominated by GEMS. Dr. Pullen received his doctorate in Medicine from LSMU, Ukraine, and multiple other degrees and certificates in the Ukraine and Canada. He is married to Chioma Pullen, and together they are building a legacy of Christ and the Kingdom.

###

Xulon Press, a division of Salem Media Group, is the world’s largest Christian self-publisher, with more than 15,000 titles published to date. Abiding and Fellowship is available online through xulonpress.com/bookstore, amazon.com, and barnesandnoble.com.

Share article on social media or email:

Major Grant Expands Support for Behavioral Health Professionals at SAC Health


SAC Health Building located in San Bernardino

SAC Health San Bernardino Campus

Thanks to the California Department of Health Care Access and Information, we will be able to expand the number of behavioral health professionals, thus increasing access to mental health and substance use disorder treatment. – Jason Lohr, CEO, SAC Health

SAC Health announced the award of a $ 1.63 million grant from the California Department of Health Care Access and Information that will help retain existing behavioral health professionals. Through the Community-Based Organization (CBO) Behavioral Health Workforce Grant Program, SAC Health will be able to provide current behavioral health providers, who have been working at SAC Health for over five years, funding to support loan repayments. The grant will also help increase SAC Health’s behavioral health personnel through recruitment activities and cultivate professional growth with stipends for clinical master and doctoral education students.

The need for therapists, social workers, psychologists and psychiatrists is greater than ever. Most of the region that SAC Health serves are deemed a Mental Health Care Professional Shortage Area as defined by the Kaiser Family Foundation. The shortage of behavioral health providers can impact low-income Medi-Cal members with long wait times for patients seeking treatment, limited access to care in certain areas, and overall reduced quality of care.

SAC Health continues to expand to meet the needs of the region. “SAC Health understands the importance of providing high-quality behavioral health care to our patients. Thanks to the California Department of Health Care Access and Information, we will be able to expand the number of behavioral health professionals, thus increasing access to mental health and substance use disorder treatment, including medication assisted treatment programming,” says Jason Lohr, MD, President and CEO of SAC Health.

SAC Health is a Federally Qualified Health Center with twelve locations throughout the Inland Empire. Serving over 50,000 patients in 2022, with over 97 percent being at or below 200 percent of the Federal Poverty Line, SAC Health is a safety-net clinic providing high quality patient-centered care throughout the region.

About SAC Health

SAC Health is the largest specialty-based and teaching health center (THC) Federally Qualified Health Center (FQHC) in the nation. SAC Health provides comprehensive services to underserved areas and populations including Medi-Cal and Medicare patients. SAC Health is recognized as a Level-3 Patient-Centered Medical Home by the National Committee for Quality Assurance (NCQA) and has over 100 community partnerships that enable the health to provide whole-person care to all its patients. SAC Health provides care in 12 locations, along with a mobile clinic, in San Bernardino and Riverside counties, including services in family medicine; pediatrics and pediatric specialties; obstetrics and gynecology, internal medicine and medical specialties; family dentistry; behavioral health; surgical specialties and more. More information on how to become a patient at SAC Health is available online at sachealth.org.

Share article on social media or email:

Bodypoint’s Global Launch of Mobile Arm Support Revolutionizes Wheelchair Mobility Products in the Complex Rehab Technology Industry


Bodypoint Moduform Dynamic Arm Support fully assembled with elbow and forearm pads and large, right-handed handblock.

Bodypoint Moduform Dynamic Arm Support

Adjustable elbow, forearm, and hand support for wheelchairs: from prevention to intervention.

The Moduform™ Dynamic Arm Support’s three points of contact will limit shoulder pain and subluxation by providing properly positioned support at the elbow, forearm, and hand, allowing for a return of upper extremity function. The arm support is versatile and can be mounted on a height-adjustable armrest to ensure proper support.

One of the product’s most innovative features, the hand block allows the fingers to flex, while encouraging the hand to return to a neutral position once the muscle tension releases. Another key differentiator of the Arm Support is the pivot plate, which allows the performance of independent range of motion (ROM) exercises to maintain function and ROM in the shoulder for ADLs such as dressing and hygiene. It can be easily accessed by the user or their caregiver, and allow progress with functional and positioning goals without replacement of parts, while the quick release tab allows for easy transfer in and out of the chair with caregiver assistance.

At the heart of the Moduform was the desire to develop an easy-to-use and anatomically correct arm support that can be utilized immediately after injury for optimal clinical outcomes. The Moduform Dynamic Arm Support (MDAS) is beneficial for clients with neurological impairment of the upper extremity. Diagnoses might include stroke (CVA), ALS, MS, and brachial plexus injury. Without question, Bodypoint has raised the bar this week for wheelchair accessory devices with the launch of the new MDAS.

“For more than 30 years, we’ve created better connections between people and wheelchairs, manufacturing postural support devices of the highest quality,” said Matthew Kosh, President and co-founder of Bodypoint. “Based on a concept by Bart Van der Heyden, world-renown PT, I am proud to now expand upon the products Bodypoint is known for with the Moduform™ Dynamic Arm Support, a welcomed new addition for the upper extremity.”

About Bodypoint:

Bodypoint develops exceptional products that enable wheelchair users to improve their lives.

For more than 30 years, Bodypoint has focused on developing better connections between people and wheelchairs, manufacturing postural support devices of the highest quality in their factory in Seattle, WA, USA.

When it comes to safety and performance, Bodypoint doesn’t take chances, backed by ISO 9001 certification for its quality management system and testing products to the latest international standards. Bodypoint collaborates with other industry leaders around the world to get the performance they deserve. Visit bodypoint.com for more information about Bodypoint and their line of best-in-class products.

Bodypoint on Social:

LinkedIn: https://www.linkedin.com/company/140202

Facebook: https://www.facebook.com/BodypointInc

Instagram: https://www.instagram.com/bodypoint_inc/

Twitter: https://twitter.com/Bodypoint_Inc

YouTube: https://www.youtube.com/BodypointInc

Website: https://www.bodypoint.com/ecommerce/

Share article on social media or email:



Breast Tomosynthesis Improves Screening in Community Settings


Our study demonstrated that more radiologists in U.S. community practice are meeting recommended performance standards with digital breast tomosynthesis than they did with digital mammography.

Researchers have found that digital breast tomosynthesis (DBT) has improved breast cancer screening performance in community practice and identifies more invasive cancers, compared to digital mammography. In addition, radiologists’ interpretive performance improved with DBT. The results of the study were published today, April 11, in Radiology, a journal of the Radiological Society of North America (RSNA).

“Our study demonstrated that more radiologists in U.S. community practice are meeting recommended performance standards with digital breast tomosynthesis than they did with digital mammography,” said lead author Christoph I. Lee, M.D., professor of radiology at the University of Washington (UW) School of Medicine in Seattle, director of the Northwest Screening and Cancer Outcomes Research Enterprise at UW, and adjunct professor of health systems and population health at the UW School of Public Health. “This is good news for women and breast cancer screening, as digital breast tomosynthesis has quickly become the most popular breast cancer screening modality in the U.S.”

After gaining U.S. Food and Drug Administration (FDA) approval in 2011, DBT was rapidly adopted in the U.S. As of September 2022, 84% of all mammography screening facilities in the U.S. had DBT units.

Breast cancer mortality reduction from routine screening is contingent upon radiologists’ interpretive performance. Since the Mammography Quality Standards Act was enacted in 1992, screening facilities and interpreting radiologists have been required to meet minimum quality standards. Beginning in 2006, the Breast Cancer Surveillance Consortium (BCSC) has published screening performance benchmarks. The BCSC is a collaborative network of breast imaging registries conducting research to assess and improve the delivery and quality of breast cancer screening and related patient outcomes.

To establish performance benchmarks for DBT screening and evaluate performance trends over time in U.S. community practices, the research team collected DBT screening exams from five BCSC registries between 2011 and 2018.

Performance measures included abnormal interpretation rate, cancer detection rate, sensitivity, specificity and false-negative rate.

Compared to BCSC digital mammography screening exams from the same time period and previously published BCSC and National Mammography Database performance benchmarks, all performance measures were higher for DBT except sensitivity and false-negative rate, which were similar to concurrent and prior digital mammography performance measures.

“Radiologists appear to perform better with digital breast tomosynthesis and have higher accuracy on screening 3D mammograms than 2D mammograms across U.S. practices,” Dr. Lee noted. “As this becomes the mainstay screening modality, we hope to see improved screening outcomes for women.”

A total of 896,101 women undergoing 2,301,766 screening exams—458,175 DBT and 1,843,591 2D digital mammography—were included in the retrospective study. The abnormal interpretation rate was 8.3%, cancer detection rate was 5.8 per 1,000 exams, sensitivity was 87.4%, and specificity was 92.2%.

With DBT, 97.6%, 91.8%, 75.0%, and 74.0% of assessed radiologists achieved the recommended acceptable performance ranges for cancer detection rate, sensitivity, abnormal interpretation rate and specificity, respectively.

Dr. Lee notes that these benchmarks are also very important for the emerging field of artificial intelligence.

“Any new AI tools aimed at improving mammography accuracy will have to revise their own performance goals based on the improved radiologist performance with DBT,” he said.

###

“National Performance Benchmarks for Screening Digital Breast Tomosynthesis: Update from the Breast Cancer Surveillance Consortium.” Collaborating with Dr. Lee were Linn Abraham, M.S., Diana L. Miglioretti, Ph.D., Tracy Onega, Ph.D., Karla Kerlikowske, M.D., Janie M. Lee, M.D., Brian L. Sprague, Ph.D., Anna N. A. Tosteson, Sc.D., Garth Rauscher, Ph.D., Erin J. A. Bowles, M.P.H., Roberta M. diFlorio-Alexander, M.D., and Louise M. Henderson, Ph.D., for the Breast Cancer Surveillance Consortium.

In 2023, Radiology is celebrating its 100th anniversary with 12 centennial issues, highlighting Radiology’s legacy of publishing exceptional and practical science to improve patient care.

Radiology is edited by Linda Moy, M.D., New York University, New York, N.Y., and owned and published by the Radiological Society of North America, Inc. (https://pubs.rsna.org/journal/radiology)

RSNA is an association of radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research, and technologic innovation. The Society is based in Oak Brook, Illinois. (RSNA.org)

For patient-friendly information on breast imaging, visit RadiologyInfo.org.

Terri-Ann Bennett, MD to Lead Maternal-Fetal Medicine at Memorial Healthcare System


Dr. Terri-Ann Bennett is a double board-certified and fellowship-trained maternal-fetal medicine specialist.

“I want people to feel heard, empowered and cared for by a dream-team of experts that help achieve their pregnancy goals and deliver a safe, supported, and beautiful experience.”- Terri-Ann Bennett, MD

Dr. Terri-Ann Bennett, a double board-certified and fellowship-trained specialist, has been named chief of Maternal-Fetal Medicine at Memorial Healthcare System. In that role she leads a department that provides care for high-risk, complex pregnancies, labor, and delivery.

Within her specialty, Bennett, a native of Jamaica, and Memorial are focused on addressing disparities in maternal morbidity and mortality that affect people from minoritized communities. “As physicians, we have an obligation to fix broken systems, overcome racism, and build trust with patients from ethnically-diverse backgrounds.

That’s why I joined Memorial, because it’s focused on safety, addresses social determinants of health, helps overcome health disparities, and delivers equitable healthcare,” she said.

Bennett completed residency and fellowship training at NYU Langone Health. She is a graduate of the University of Miami’s Miller School of Medicine and Blanche Ely High School’s medical magnet program.

Bennett says the maternal-fetal leadership role provides an additional opportunity to positively impact Black and immigrant families beyond the clinical care she provides. “I understand their background, culture, and am positioned to change how they may view physicians. I strive to show there’s a real person behind the white coat.

I want people to feel heard, empowered and cared for by a dream-team of experts that help achieve their pregnancy goals and deliver a safe, supported, and beautiful experience.”

To learn more about Memorial’s maternal-fetal care program, visit http://www.mhs.net/services/high-risk-pregnancy-care.

# # #

South Florida-based Memorial Healthcare System (http://www.mhs.net) is a national leader in quality care and patient, physician, and employee satisfaction. Its commitment to deeper caring and smarter health prioritizes a person-centered approach that has delivered safe, positive outcomes for more than 70 years.

Featuring multi-disciplinary collaboration, research, innovation, and transparency within its many facilities, Memorial is focused on removing barriers, increasing access, and providing equitable care throughout the region. It employs a staff of more than 15,000 and operates six hospitals, numerous primary, urgent, and 24/7 care facilities, a health specialty center, and nursing home.

To learn more, visit mhs.net and connect on Facebook, Twitter, Instagram, YouTube, and LinkedIn.

Share article on social media or email:

World Parkinson Coalition® Partners with Barcelona Community to become “Parkinson’s Ready” Ahead of 6th World Parkinson Congress


World Parkinson Coalition

World Parkinson Coalition

“It’s a great relief for people with Parkinson’s disease to know that you can find public servants educated about the disease and ready to help.” – Fulvio Capitanio, person living with PD

In honor of World Parkinson’s Day, the World Parkinson Coalition (WPC), together with Associació Catalana per al Parkinson, Barcelona Turisme Convention Bureau and sponsored by AbbVie, announced today the launch of its Make the City “Parkinson’s Ready” program ahead of the 6th World Parkinson Congress taking place July 4-7, 2023. The program will help the Barcelona community prepare to welcome congress attendees living with Parkinson’s disease (PD) and their care partners and is focused on equipping people working on the front lines of transportation, hotel staff, convention center staff, as well as local police and customs officials at the airport with the opportunity to learn about Parkinson’s so they can have positive experiences interacting with delegates who live with Parkinson’s during the Congress.

“Parkinson’s disease is one of the fastest growing neurological disorders and a significant challenge for people living with PD is traveling comfortably and safely,” said Elizabeth “Eli” Pollard, Executive Director of World Parkinson Coalition. “PD is complicated and often misunderstood, so accessibility issues and lack of PD awareness by local staff can present a myriad of problems causing additional stressors for those living with the disease.”

The “Parkinson’s Ready” program is designed to:


  • Prepare Barcelona to welcome the more than 4,000 delegates during this year’s World Parkinson Congress, some of whom live with Parkinson’s
  • Ensure congress attendees have a welcoming and safe experience while in Barcelona
  • Educate public services and hospitality industry leaders to better understand PD and leave the city smarter than before


–

“The “Parkinson’s Ready” program was designed to prioritize the needs of those living with this condition and provide empathetic and practical training to equip the Barcelona community to meet their needs,” said Roser Roigé, president of Associació Catalana per al Parkinson.

“Barcelona has proven itself as a pioneering Smart City through the renewal of smart transport and urban infrastructures – but, above all, it has been a pioneer in understanding how to harness technology to offer better sustainability, inclusivity and self-management of the city,” said Christoph Tessmar, Barcelona Turisme Convention Bureau Managing Director. “Our work with the “Parkinson’s Ready” training is making the city even smarter. This program will leave a significant positive impact on our society and across the different groups involved in the trainings, including public transportation, police, airport and hotels.”

“Parkinson’s Ready” will be offered in a series of short trainings in April, May and June, the months leading up to the Congress, which will take place in July. The trainings will include specialized elements specific to each group, including police officers, first responders and hotel, convention center and airport staff. The World Parkinson Coalition has a legacy in making cities more inclusive through this program, which began in 2010.

“The collaborative and thoughtful approach taken by “Parkinson’s Ready” organizers for Barcelona is truly special,” said Selma Peláez, neurophysiotherapist at Hospital Clínic de Barcelona, Associació Catalana per al Parkinson and instructor for the “Parkinson’s Ready” program. “This year’s trainings will set the foundation of formalizing a protocol of community education for Parkinson’s disease, and we look forward to Barcelona setting an example to educate other communities around the world.

”As part of WPC’s legacy, after the congress ends the PD knowledge will stay in Barcelona with those who were trained, allowing them to support their communities, including more than 160,000 people living with PD in Spain, and future guests across airports, hotels, meeting centers, public transportation, taxis and beyond.

“Traveling long distance and moving around in a big city can be much more challenging than one can imagine,” said Fulvio Capitanio, person living with PD, economist, co-founder of Unidos contra el Párkinson and World Parkinson Congress Steering Committee member. “It’s a great relief for people with Parkinson’s disease to know that you can find public servants educated about the disease and ready to help.

“World Parkinson’s Day is honored every year on April 11 to build global awareness for PD and empower those living with the condition and patient advocacy groups to speak up about the impact it has on their lives.

###

About the World Parkinson Coalition® and WPC 2023

The World Parkinson Coalition Inc provides an international forum for learning about the latest scientific discoveries, medical practices, caregiver initiatives and advocacy work related to Parkinson’s disease. The triennial World Parkinson Congresses provide a space for the global Parkinson’s community of researchers, clinicians, health care professionals, people with Parkinson’s and their care partners to meet in person, network, and discuss advances in Parkinson’s research, improve understanding and promote advocacy worldwide, while influencing future research and care options. The WPC 2023 will attract more than 4,000 delegates.

About Parkinson’s Disease

Affecting nearly one million Americans and 10 million people worldwide, Parkinson’s disease is the fastest growing neurodegenerative disease on the planet. While Parkinson’s disease is characterized by limited functional ability, a variety of nonmotor and motor symptoms significantly impact the quality of life of both people living with Parkinson’s disease and their care partners. This can include resting tremor, muscle rigidity, paid, fatigue, anxiety and depression.

About Associació Catalana per al Parkinson

Associació Catalana per al Parkinson (The Catalan Association for Parkinson’s) is a non-profit organization born in 1985 in Barcelona. It was the first association of patients with Parkinson’s disease in Spain. Since then, the organization has been working to provide care and advice to people affected by Parkinson’s disease and their families. In 1997, it was declared a public utility by the Spanish government, and in 2020, it received a distinction from the Catalan Society of Neurology for its neurorehabilitative work and social awareness. Based in different towns in Catalonia, it provides rehabilitation therapies, social care, home care, and health education.

About Barcelona Turisme Convention Bureau

The Barcelona Convention Bureau (BCB) is a specialised division of Turisme de Barcelona that promotes Barcelona as a congress, convention and incentive travel destination, and offers free and impartial advice to professionals interested in organising their meeting in Barcelona. Founded in 1983, BCB was a pioneer in this field in Spain. Four decades of experience have given us in-depth knowledge of the city, creating close working relationships with companies and associations in the meetings industry.

About AbbVie in Neuroscience

At AbbVie, our commitment to preserve the personhood of those living with neurological and psychiatric disorders is unwavering. Every challenge in this uncharted territory makes us more determined and drives us harder to discover and deliver solutions for patients, care partners and clinicians. AbbVie’s Neuroscience portfolio consists of approved therapies in neurological and psychiatric disorders, including bipolar I disorder, major depressive disorder, migraine, Parkinson’s disease, post-stroke spasticity, schizophrenia and others along with a robust pipeline.

[1] Daniel Weintraub, Cynthia L. Comella and Stacy Horn. (2008). Parkinson’s Disease – Part 1: Pathophysiology, Symptoms, Burden, Diagnosis, and Assessment. Cranbury: American Journal of Managed Care. (REF-46529)